. In contrast, no significant treatment benefit could be demonstrated for patients with stage I disease (3, 4) leaving surgery alone as the only curative treatment option. Nevertheless, five-year survival rates in stage I NSCLC patients are as low as 50% in stage IB and reach only 70% in IA patients (5, 6) , indicating a considerable high-risk subpopulation that could benefit from more aggressive therapy. Advances in surgical techniques, for example video-assisted thoracic surgery (VATS) are expected to increase the number of patients with improved performance status and the ability to undergo additional post-surgical treatment options (7) (8) (9) . In addition, low-dose computed tomographic screening for high-risk populations will lead to increased numbers of patients with early stage diagnoses (10) .
Many clinical and molecular factors have been evaluated as possible markers to improve staging and treatment decisions in stage I patients. This includes the use of pathological parameters, such as tumor size, to guide adjuvant treatment in stage IB (4) . Histologic (11) , immunohistochemistry (12) and genetic markers (13) Author Manuscript Published OnlineFirst on September 18, 2013; DOI: 10.1158/1078-0432.CCR- and outcome in NSCLC (reviewed in 14, 15) . However, most of these expression profiles, developed from fresh frozen samples, have never been rigorously tested in formalin-fixed and paraffin-embedded (FFPE) tissue samples and their performance on clinical samples remains unknown. Recently, a 14-gene profile was developed on a quantitative PCR platform and tested in two large cohorts of non-squamous, resectable non-small cell lung cancer showing prognostic separation of low and high risk patients (16, 17) . However, neither the 14-gene signature nor any other expression profile has gained sufficient acceptance to become standard of care.
In contrast, tumor RNA signatures have been highly successful as prognostic tools in breast cancer. A careful evaluation and comparison of prognostic breast RNA profiles revealed a common component of cell cycle regulated mRNAs which contains the major prognostic power of each expression profile (18) (19) (20) (21) . The expression levels of cell cycle progression (CCP) genes measure tumor growth irrespective of the underlying genetic aberrations. The prognostic power of proliferation in lung cancer was first shown in early studies with the mitotic index (22) as well as the examination of single gene expression data (23, 24, 25) . More recently, proliferation has been the focus of one of fourteen methods applied to the microarray data in the Director's Consortium (26) . In addition, a proliferation signature derived from meta-analysis of breast cancer data was successfully applied to lung cancer (20) and the prognostic signature derived by Park et al (27) has a strong cell cycle related component. We therefore decided to test an independently developed signature of cell cycle genes in lung adenocarcinoma. The cell cycle proliferation (CCP) score was first applied to prostate cancer where it is a strong predictor of death from prostate cancer in biopsies (28) This study investigates the utility of the CCP score as a predictor of survival in patients with early stage lung adenocarcinoma. To focus on the group of patients with the most possible clinical utility, we selected stage I and II patients with the goal of identifying low-risk patients who may forego adjuvant treatment and high-risk patients with increased need for more aggressive treatment options. The CCP score was tested retrospectively in three large, independent patient sets for its ability to predict death from lung cancer.
Patients & Methods
Microarray data. Clinical and pathological characteristics of the different patient sets with microarray data tested are detailed in Table 1 Figure S1A) . CEL files and patient data of an adenocarcinoma cohort collected at the University of Tokyo are available under GSE31210 from the GEO database. Patient selection, sampling and processing have been described previously (30) . All patients in the GSE31210 set were chemo-naive. From the total data set of 226 stage I and II samples, 22 with incomplete resection were excluded, leaving 204 patients for analysis (Supplementary Figure S1A) . 
Results
Test of the CCP signature in lung adenocarcinoma microarray datasets. We tested the ability of the CCP score to predict five-year death from disease after resection with curative intent in public expression microarray data. Since the CCP score had been defined previously, no further gene selection or training in lung cancer was necessary.
256 stage I-II lung adenocarcinoma patients with complete clinical data from the DC cohort (26) and 204 stage I-II patients from a Japanese study on lung adenocarcinoma (30) were analyzed independently. In both cohorts patients had undergone complete resections and RNA from frozen surgery specimens had been subjected to gene expression analysis on Affymetrix expression microarrays. Twenty-eight percent of the DC cohort had died at 5 years, providing 71 events for analysis. Within five years from surgery 25 deaths were observed in the GSE31210.
In univariate Cox proportional hazards analysis, the CCP score was significantly predictive of five-year outcome in both the DC cohort (p=0.00014) and the Japanese patient set (p=0.0010). The hazard ratio per interquartile range of the CCP score was 2.08 (95% CI 1.43-3.02) in the DC cohort and 2.25 (95% CI 1.42-3.56) in the Japanese data set. As expected, stage was highly prognostic (p<0.0001) in the DC patients. As shown in Table 2 , among clinical variables, only adjuvant treatment in the DC cohort was significantly associated with outcome. However, adjuvant treatment did not reduce the risk of death (HR 2.78, 95% CI (1.69-4.58)). In the Japanese cohort, EGFR and Table 2 .
We tested for an interaction between the CCP score and any of the clinical variables by introducing an interaction term into the model. None of these interaction terms reached significance at the 5% level. Scaled Schoenfeld residuals versus untransformed time were used to evaluate the appropriateness of the proportional hazards assumption. No evidence was found supporting time dependence for the hazard ratio of the CCP score. To evaluate the possibility that CCP score might have a non-linear effect, second-and third-order polynomials for CCP score were tested in Cox proportional hazards models but were not significant at the 5% level.
Kaplan-Meier curves visualize the separation of low and high risk patients according to CCP score ( Figure 1A-B) . For illustration purposes, the patient sets were divided into equally sized groups based on terciles of the CCP score. For these low, intermediate and high CCP score patient groups five-year survival rates were 84%, 68%
and 56%, respectively, in the DC cohort and 97%, 92% and 70% in the Japanese data Results from univariate and multivariate Cox proportional hazards analysis are summarized in Table 3 . In univariate analysis, the CCP score was the most significant predictor of outcome (p=0.00033). An increase in CCP score resulted in increased risk of dying from lung cancer with a hazard ratio of 2.10 (95% CI 1.39-3. To illustrate the results, a Kaplan-Meier curve using the same terciles of the CCP score as used for the analysis of the microarray data is presented in Figure 1C . Fiveyear lung cancer specific survival for the low CCP patient group was 92%, decreasing to 79% and 73% in the intermediate and high CCP patients. Heterogeneity analysis between the three data sets (DC, GSE31210 and MDACC/IEO) did not identify any significant cohort differences. This is supported by the consistent hazard ratios for the CCP score observed the three data sets ( Figure 1D ).
Low CCP scores are clearly associated with improved outcome and the predicted probability of five-year death from lung cancer increases as a function of the CCP score. Figure 2A shows the relationship between the risk of lung cancer related death and the CCP score measured by quantitative PCR in the FFPE cohort. The CCP score provides additional prognostic information within each stage group. This is visualized in Figure   2A by the wide distribution of CCP scores within each stage and supported by the hazard ratio in multivariate Cox proportional hazards regression. Figure S2) . Cancer-specific survival rates at five years were 90% for patients with CCP scores below the median and 77% for patients with scores higher than the median CCP. The effect was similar in the MDACC cohort (low CCP 90%, high CCP 79%) and the IEO patients (low CCP 90%, high CCP 75%).
Prediction of adjuvant treatment benefit.
To explore the possibility of using the CCP score as a predictive tool, we examined the relationship between CCP score and absolute benefit from adjuvant treatment in the MDACC cohort. The 207 patients included 46 patients who had received adjuvant therapy. Most importantly, the treated patient set from the MDACC cohort showed significant improvement (p=0.030, HR=0.32) in 5 year survival (Kaplan-Meier estimate 92.25%, 95% CI 77.70%-97.46%) compared to patients not receiving adjuvant treatment (Kaplan-Meier estimate 77.56%, 95% CI 69.46%-83.76%). The number of treated patients in the IEO data set was insufficient to provide statistical power and adjuvant therapy provided no measurable survival benefit. Therefore, association with treatment benefit was restricted to the MDACC cohort. To evaluate the relationship between CCP score and absolute treatment benefit, we categorized CCP scores as being high or low using the median 
The data presented here establish the CCP score as a reliable prognostic marker in early stage lung adenocarcinoma. The CCP score effectively identified patients groups of reduced or increased risk of death after surgical resection and added significant prognostic information not contained in clinical variables. Importantly, none of the data sets described in this study had been used in the development of the gene profile. The composition of the signature centers on a characteristic trait of tumor cells.
In contrast, other prognostic profiles aggregate the highest ranked genes in survival analysis from a single training data set into a prognostic score. Inevitably, these lists contain genes that appear correlated with outcome due to statistical noise rather than true biological association. Not surprisingly, many of these signatures lack robustness when applied to additional data sets. In contrast, the CCP signature was previously shown to be a superior prognostic tool in prostate cancer (28, 29) . year mortality in cohorts of mixed stages and in a sub-analysis of tumors <2cm (17) .
The Lung RS study supports the idea that expression signatures can be established for use in formalin fixed lung tissue and that they may have similar importance in modifying treatment decisions in lung adenocarcinoma as pioneered in estrogen receptor positive breast cancer. The present study distinguishes itself from the 14 gene score by focusing on a gene set that is directly related to a well-established feature of tumor cells. In addition, the choice of outcome measure is more relevant to the intended clinical application. For the purpose of informing treatment decisions in resectable lung cancer, association with overall survival is less informative than prediction of lung-cancer specific survival. In a patient population that is often of advanced age and frequently burdened with co-morbidities, potential treatment benefits need to be weighed against therapy side effects in the context of both non-cancer related and cancer-specific mortality.
Adjuvant chemotherapy in NSCLC has limited effectiveness and the estimated absolute benefit in a large meta-analysis was a rather modest at approximately 5% (1, 3) . Therefore, it is desirable not only to identify patients at high risk of lung cancerrelated death, but also those patients with the greatest likelihood of therapeutic benefit.
Patients not likely to benefit could be directed to clinical trials or avoid the treatment and its toxicities altogether. Showing the association of a biomarker with treatment benefit requires a cohort with one treated and one untreated arm and a measurable treatment benefit between both arms. In many cohorts treatment fails to improve outcome. For example, in the DC data set, those patients treated fare worse than untreated patients (14) . The data set from MD Anderson Cancer Center included patients who had received adjuvant therapy and, more importantly, the treated patients showed a significant treatment benefit. We observed a statistically significant association between treatment benefit and CCP score. This observation requires further confirmation in other data sets, but it suggests that the CCP score may provide predictive information about therapy benefit in addition to its prognostic utility. We recognize that for clinical purposes a risk threshold that guides treatment decisions is useful. However, in this first study in lung adenocarcinoma, we avoided setting predefined thresholds since treatment decisions in resectable NSCLC are subject to other important considerations, most notably stage, but also age, performance status and preexisting conditions. All of these factors influence the balance between risk of cancer related death, risk of noncancer related death and expected therapy benefit. A clinically meaningful risk threshold for recommending treatment should be drawn when these factors are appropriately integrated. We will address this issue with a combined score in further prospectively collected studies
In summary, our study shows convincingly that the CCP score is a significant prognostic marker in lung adenocarcinoma that stratifies early stage patients more effectively than conventional clinical parameters. Its CLIA-certified quantitative PCR platform is compatible with clinical practice patterns and may help differentiate patient populations with early stage disease to improve treatment selection.
Research. (B) Absolute benefit from adjuvant treatment depending on CCP score. Association of the expression score with treatment benefit was derived from the difference in survival ratios between the treated and untreated patients in the MDACC cohort.
